Capital Planning LLC Has $371,000 Holdings in Eli Lilly and Company (NYSE:LLY)

Capital Planning LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 15.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 481 shares of the company’s stock after purchasing an additional 65 shares during the period. Capital Planning LLC’s holdings in Eli Lilly and Company were worth $371,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. KMG Fiduciary Partners LLC lifted its stake in shares of Eli Lilly and Company by 3.3% in the 4th quarter. KMG Fiduciary Partners LLC now owns 26,361 shares of the company’s stock valued at $20,350,000 after purchasing an additional 831 shares during the period. Decker Retirement Planning Inc. acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $189,000. Occidental Asset Management LLC increased its holdings in Eli Lilly and Company by 1.2% in the fourth quarter. Occidental Asset Management LLC now owns 1,475 shares of the company’s stock worth $1,139,000 after purchasing an additional 18 shares in the last quarter. StoneCrest Wealth Management Inc. lifted its stake in Eli Lilly and Company by 6.8% in the fourth quarter. StoneCrest Wealth Management Inc. now owns 5,268 shares of the company’s stock valued at $4,067,000 after buying an additional 336 shares during the period. Finally, Empirical Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 160.1% during the 4th quarter. Empirical Asset Management LLC now owns 130,451 shares of the company’s stock worth $100,708,000 after buying an additional 80,301 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $726.24 on Friday. The company has a fifty day moving average price of $783.25 and a 200-day moving average price of $856.02. The firm has a market cap of $689.43 billion, a price-to-earnings ratio of 78.51, a PEG ratio of 1.66 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 1 year low of $612.70 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. As a group, equities research analysts predict that Eli Lilly and Company will post 13.14 EPS for the current fiscal year.

Eli Lilly and Company announced that its board has approved a share repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Bank of America reiterated a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Barclays cut their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, January 1st. Finally, Citigroup upped their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Friday, October 25th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.